Clinical Trial

Biologics and Sublingual Immunotherapy

Study acronym: BSIPL
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.
Trial Details
NCT Number NCT06027073
Lead Sponsor Medical University of Silesia
Collaborators: Centrum Medyczne Andrzej Bożek
Conditions Asthma, Allergic
Enrollment 150 participants
Start Date 2024-05-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-07